SUPRIYA LIFESCIENCE
|
SUPRIYA LIFESCIENCE Last 5 Year Financial Ratios History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 25.98 | 23.35 | 14.80 | 11.16 | 18.86 |
| CEPS(Rs) | 29.51 | 25.89 | 16.76 | 12.63 | 20.12 |
| DPS(Rs) | 1.00 | 1.00 | 0.80 | 0.60 | 0.60 |
| Book NAV/Share(Rs) | 148.81 | 123.84 | 101.31 | 86.91 | 76.50 |
| Tax Rate(%) | 23.90 | 24.36 | 28.11 | 27.23 | 26.75 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 32.24 | 33.37 | 27.16 | 24.87 | 36.36 |
| EBIT Margin(%) | 30.34 | 32.01 | 26.41 | 24.51 | 35.93 |
| Pre Tax Margin(%) | 30.04 | 31.78 | 25.61 | 23.91 | 35.21 |
| PAT Margin (%) | 22.86 | 24.04 | 18.41 | 17.40 | 25.80 |
| Cash Profit Margin (%) | 25.97 | 26.65 | 20.86 | 19.69 | 27.51 |
| Performance Ratios | |||||
| ROA(%) | 16.90 | 18.42 | 13.66 | 11.56 | 25.73 |
| ROE(%) | 19.06 | 20.74 | 15.73 | 13.66 | 34.34 |
| ROCE(%) | 25.30 | 27.62 | 22.31 | 18.71 | 43.34 |
| Asset Turnover(x) | 0.74 | 0.77 | 0.74 | 0.66 | 1.00 |
| Sales/Fixed Asset(x) | 1.37 | 1.73 | 1.91 | 1.95 | 3.40 |
| Working Capital/Sales(x) | 2.22 | 2.20 | 2.02 | 1.40 | 1.48 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.73 | 0.58 | 0.52 | 0.51 | 0.29 |
| Receivable days | 70.59 | 57.43 | 55.39 | 70.62 | 58.51 |
| Inventory Days | 55.45 | 47.52 | 56.71 | 73.53 | 51.10 |
| Payable days | 133.19 | 115.90 | 101.89 | 114.26 | 93.20 |
| Valuation Parameters | |||||
| PER(x) | 21.75 | 31.41 | 22.42 | 17.08 | 26.13 |
| PCE(x) | 19.15 | 28.33 | 19.79 | 15.10 | 24.50 |
| Price/Book(x) | 3.80 | 5.92 | 3.27 | 2.19 | 6.44 |
| Yield(%) | 0.18 | 0.14 | 0.24 | 0.31 | 0.12 |
| EV/Net Sales(x) | 5.40 | 8.36 | 4.55 | 3.02 | 7.09 |
| EV/Core EBITDA(x) | 14.59 | 21.51 | 13.90 | 10.07 | 16.97 |
| EV/EBIT(x) | 16.10 | 23.27 | 15.19 | 11.01 | 17.78 |
| EV/CE(x) | 3.73 | 5.84 | 3.18 | 1.95 | 5.90 |
| M Cap / Sales | 5.49 | 8.48 | 4.68 | 3.33 | 7.48 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 18.86 | 22.12 | 23.73 | -13.04 | 35.49 |
| Core EBITDA Growth(%) | 13.18 | 45.05 | 34.88 | -37.54 | 24.37 |
| EBIT Growth(%) | 10.89 | 46.51 | 34.97 | -40.14 | 23.37 |
| PAT Growth(%) | 11.26 | 57.80 | 32.56 | -40.81 | 22.83 |
| EPS Growth(%) | 11.26 | 57.80 | 32.56 | -40.81 | 11.69 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | 0.02 | 0.03 |
| Current Ratio(x) | 4.40 | 5.07 | 5.03 | 4.85 | 4.99 |
| Quick Ratio(x) | 3.08 | 3.71 | 3.96 | 3.64 | 4.06 |
| Interest Cover(x) | 100.13 | 138.28 | 33.18 | 41.04 | 50.37 |
| Total Debt/Mcap(x) | - | - | - | 0.01 | 0.01 |
Compare Financial Ratios of peers of SUPRIYA LIFESCIENCE
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUPRIYA LIFESCIENCE | ₹6,592.1 Cr | -7.6% | -12.6% | 16.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,204.0 Cr | -1% | -5.5% | 5.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹238,497.0 Cr | -2.6% | -3.9% | 38.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹170,481.0 Cr | -1.7% | -10.2% | 30.5% | Stock Analytics | |
| CIPLA | ₹108,012.0 Cr | 0.9% | -3.2% | -15.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,207.0 Cr | -0.6% | 1% | -0.1% | Stock Analytics | |
SUPRIYA LIFESCIENCE Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUPRIYA LIFESCIENCE | -7.6% |
-12.6% |
16.2% |
| SENSEX | -1.6% |
-2.3% |
-11.5% |
You may also like the below Video Courses
